VERU Veru Corporation: Price-to-Projected Revenue Ratio
Veru Inc. relies on external contractors for drug development and testing. This P/S forward metric chart on GURU.Markets visualizes market expectations, where the metric value stands at 4.90. However, the potential failure of new drugs creates risks for the share price. To avoid competitive pressure, the company is implementing software to preserve muscle mass during obesity treatment.
Analytical breakdowns for Veru Inc.
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Veru Inc.|VERU - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Veru Inc.|VERU - Company Aggregate Debt|Debts to Book Capitalization Veru Corporation|VERU - Company Long-Term Liabilities|Company Current Liabilities Veru|Quick Liquidity Indicator verupharma.com
- net income and valuation multiples indicators:
VERU - Company Net Income|Projected Future Earnings Veru Inc.|VERU - Market Cap to Earnings|Future Price to Earnings Veru Pharma|VERU - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Veru Corporation|VERU - Operating profit EBITDA|Net earnings per share (EPS TTM) Veru|VERU - Net earnings per share for the last 12 months|Quarterly EPS earnings growth verupharma.com|VERU - Earnings growth in current year|Net earnings per share growth forecast for next year Veru Inc.
- total revenue and sales volume data:
Fundamental company valuation:Veru VERU
The forward P/S ratio reflects the market value of Veru Inc. (VERU) relative to expected revenue, allowing for an assessment of the premium paid for future income streams. By analyzing the forward P/S multiple, an investor determines the balance between risk and return, which is critical for a biopharmaceutical brand whose capitalization depends on the success of developments in oncology and the fight against viral threats.
Competitors of Veru Inc. (VERU)
Forward P/S Multiple ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD - Price-to-Projected Revenue Ratio|Forward Price to Sales AAPG (Ascentage Pharma Corp)|CGON (CG Oncology, Inc.) - Forward Price-to-Revenue Multiple|urogen.com (URGN) - Forward P/S Multiple|Forward Price-to-Revenue Multiple BCAX|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|Market Cap to Expected Sales Ratio Delcath Corp|Price-to-Projected Revenue Ratio Y-mAbs Therapeutics YMAB|AURA: Market Cap to Projected Revenue|Candel - Forward P/S Multiple|Accuray Inc (ARAY) - Forward Price-to-Revenue Multiple|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|ACTU - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CTOR|Price-to-Projected Revenue Ratio HURA|Forward P/S Multiple TARA|FATE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|Forward Price to Sales TCRX|CSBR: Forward Price-to-Revenue Multiple|XBIT - Forward P/S Multiple|CVM: Forward P/S Multiple|Forward Price-to-Revenue Multiple OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Forward P/S Multiple Artiva|Price-to-Projected Revenue Ratio Adlai Nortye Ltd. (ANL)|tempesttx.com - Market Cap to Projected Revenue|Forward P/S Multiple XLO (Xilio Therapeutics)|RENB - Forward Price-to-Revenue Multiple|Mural Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|CytoMed Therapeutics Limited - Forward Price to Sales|Forward Price-to-Revenue Multiple CRIS|APLM: Forward Price to Sales|Forward P/S Multiple THAR|Forward Price-to-Revenue Multiple advanbiomed.com ADVB|Genprex, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Projected Revenue Ratio|Forward Price to Sales XBIO (Xenetic Biosciences)|SLRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|Forward Price-to-Revenue Multiple AONC|Price-to-Projected Revenue Ratio BGNE|Forward P/S Multiple CKPT|ELEV - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio iCAD ICAD|Forward Price to Sales IKNA|NTBL: Forward Price-to-Revenue Multiple|VIRX - Forward P/S Multiple|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
